Human umbilical cord-derived mesenchymal stem cell-exosomal miR-627-5p ameliorates non-alcoholic fatty liver disease by repressing FTO expression
- PMID: 34410623
- DOI: 10.1007/s13577-021-00593-1
Human umbilical cord-derived mesenchymal stem cell-exosomal miR-627-5p ameliorates non-alcoholic fatty liver disease by repressing FTO expression
Abstract
Non-alcoholic fatty liver disease (NAFLD) is a spectrum of liver disorders. Human umbilical cord-derived mesenchymal stem cells (hUC-MSCs)-based therapy is currently considered to be an effective treatment for NAFLD. The present study aimed to determine whether hUC-MSCs-exosomes have a hepatoprotective effect on NAFLD. We constructed NAFLD rat model by high-fat high-fructose feeding. Liver cells (L-O2) were treated with palmitic acid (PA) to mimic NAFLD model. NAFLD rats and PA-treated L-O2 cells were treated with hUC-MSCs-exosomes, and then we determined the influence of exosomes on liver damage and glucose and lipid metabolism in vivo and in vitro. We found that hUC-MSCs-exosomes exhibited an up-regulation of miR-627-5p. Exosomal miR-627-5p promoted cell viability and repressed apoptosis of PA-treated L-O2 cells. Exosomal miR-627-5p also enhanced the expression of G6Pc, PEPCK, FAS and SREBP-1c and suppressed PPARα expression in PA-treated L-O2 cells. Moreover, miR-627-5p interacted with fat mass and obesity-associated gene (FTO) and inhibited FTO expression in L-O2 cells. MiR-627-5p-enriched exosomes improved glucose and lipid metabolism in L-O2 cells by targeting FTO. In vivo, exosomal miR-627-5p ameliorated insulin tolerance, liver damage, glucose and lipid metabolism and reduced lipid deposition in NAFLD rats. Exosomal miR-627-5p also reduced body weight, liver weight, and liver index (body weight/liver weight) in NAFLD rats. In conclusion, these data demonstrate that HUC-MSCs-derived exosomal miR-627-5p improves glucose and lipid metabolism and alleviate liver damage by repressing FTO expression, thereby ameliorating NAFLD progression. Thus, hUC-MSCs-exosomes may be a potential treatment for NAFLD.
Keywords: Exosomes; FTO; Glucose and lipid metabolism; Human umbilical cord-derived mesenchymal stem cells; Insulin tolerance; Liver damage; Non-alcoholic fatty liver disease; miR-627-5p.
© 2021. Japan Human Cell Society.
Similar articles
-
Current perspectives on mesenchymal stem cells as a potential therapeutic strategy for non-alcoholic fatty liver disease.World J Stem Cells. 2024 Jul 26;16(7):760-772. doi: 10.4252/wjsc.v16.i7.760. World J Stem Cells. 2024. PMID: 39086561 Free PMC article. Review.
-
Exosomes derived from human umbilical cord mesenchymal stem cells ameliorate experimental non-alcoholic steatohepatitis via Nrf2/NQO-1 pathway.Free Radic Biol Med. 2022 Nov 1;192:25-36. doi: 10.1016/j.freeradbiomed.2022.08.037. Epub 2022 Sep 10. Free Radic Biol Med. 2022. PMID: 36096356
-
Liraglutide in combination with human umbilical cord mesenchymal stem cell could improve liver lesions by modulating TLR4/NF-kB inflammatory pathway and oxidative stress in T2DM/NAFLD rats.Tissue Cell. 2020 Oct;66:101382. doi: 10.1016/j.tice.2020.101382. Epub 2020 May 12. Tissue Cell. 2020. PMID: 32933722
-
Human umbilical cord mesenchymal stem cells-derived exosomal microRNA-181a retards nasopharyngeal carcinoma development by mediating KDM5C.J Cancer Res Clin Oncol. 2021 Oct;147(10):2867-2877. doi: 10.1007/s00432-021-03684-6. Epub 2021 Jul 4. J Cancer Res Clin Oncol. 2021. PMID: 34218325
-
Fat Mass and Obesity Associated (FTO) Gene and Hepatic Glucose and Lipid Metabolism.Nutrients. 2018 Nov 1;10(11):1600. doi: 10.3390/nu10111600. Nutrients. 2018. PMID: 30388740 Free PMC article. Review.
Cited by
-
Current perspectives on mesenchymal stem cells as a potential therapeutic strategy for non-alcoholic fatty liver disease.World J Stem Cells. 2024 Jul 26;16(7):760-772. doi: 10.4252/wjsc.v16.i7.760. World J Stem Cells. 2024. PMID: 39086561 Free PMC article. Review.
-
Immunomodulatory properties of mesenchymal stromal/stem cells: The link with metabolism.J Adv Res. 2023 Mar;45:15-29. doi: 10.1016/j.jare.2022.05.012. Epub 2022 May 31. J Adv Res. 2023. PMID: 35659923 Free PMC article. Review.
-
m6A Regulator-Mediated RNA Methylation Modification Patterns are Involved in the Pathogenesis and Immune Microenvironment of Depression.Front Genet. 2022 Apr 11;13:865695. doi: 10.3389/fgene.2022.865695. eCollection 2022. Front Genet. 2022. PMID: 35480327 Free PMC article.
-
N6 -Methyladenosine and Rheumatoid Arthritis: A Comprehensive Review.Front Immunol. 2021 Sep 24;12:731842. doi: 10.3389/fimmu.2021.731842. eCollection 2021. Front Immunol. 2021. PMID: 34630412 Free PMC article. Review.
-
A comprehensive framework for managing metabolic dysfunction-associated steatotic liver disease: analyzing novel risk factors and advances in nanotechnology-based treatments and diagnosis.RSC Med Chem. 2024 Jun 13;15(8):2622-2642. doi: 10.1039/d4md00420e. eCollection 2024 Aug 14. RSC Med Chem. 2024. PMID: 39149095 Review.
References
-
- Lieber CS. CYP2E1: from ASH to NASH. Hepatol Res. 2004;28(1):1–11. https://doi.org/10.1016/j.hepres.2003.08.001 . - DOI - PubMed
-
- Marchesini G, Bugianesi E, Forlani G, Cerrelli F, Lenzi M, Manini R, et al. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology. 2003;37(4):917–23. https://doi.org/10.1053/jhep.2003.50161 . - DOI - PubMed
-
- de Alwis NM, Day CP. Non-alcoholic fatty liver disease: the mist gradually clears. J Hepatol. 2008;48:S104–12. https://doi.org/10.1016/j.jhep.2008.01.009 . - DOI - PubMed
-
- Watt MJ, Miotto PM, De Nardo W, Montgomery MK. The liver as an endocrine organ-linking NAFLD and insulin resistance. Endocr Rev. 2019;40(5):1367–93. https://doi.org/10.1210/er.2019-00034 . - DOI
-
- Chen L, Chen XW, Huang X, Song BL, Wang Y, Wang Y. Regulation of glucose and lipid metabolism in health and disease. Sci China Life Sci. 2019;62(11):1420–58. https://doi.org/10.1007/s11427-019-1563-3 . - DOI - PubMed
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous